BioCentury
ARTICLE | Clinical News

China approves Descovy, Harvoni, Hemlibra

December 7, 2018 6:38 PM UTC

China's National Medical Products Administration (NMPA) has issued new approvals for three drugs marketed in the U.S. and EU: Descovy emtricitabine/tenofovir alafenamide and Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), and Hemlibra emicizumab-kxwh from Roche (SIX:ROG; OTCQX:RHHBY).

Hemlibra's Chinese approval to treat hemophilia A comes a little over a year after FDA approved the drug in the same indication. The EU also approved Hemlibra in the indication in February (see "EC Approves Roche's Hemlibra for Hemophilia A")...